We are live on ! Find out more
RG

Redmile Group Portfolio holdings

AUM $1.49B Turnover 10.26%
1-Year Est. Return 208.7%
This Fund
S&P 500
This Quarter Est. Return
+6.36%
1 Year Est. Return
+208.7%
3 Year Est. Return
+777.5%
5 Year Est. Return
+1,114.43%
10 Year Est. Return
+23,630.52%
AUM
$6.76B
AUM Growth
-$342M
Cap. Flow
-$367M
Cap. Flow %
-5.43%
Top 10 Hldgs %
43.88%
Holding
93
New
7
Increased
14
Reduced
55
Closed
7
Avg Time Held
1.5 years
Top 10 Avg Time Held
1.8 years
Top 20 Avg Time Held
1.2 years

Top Buys

Rank Stock Value
1
VERV icon
Verve Therapeutics
VERV
+$80.4M
2
ZY
Zymergen Inc. Common Stock
ZY
+$60.1M
3
SKIN icon
SkinHealth Systems
SKIN
+$59.8M
4
ONEM
1Life Healthcare
ONEM
+$41.7M
5
LFST icon
Lifestance Health
LFST
+$33.2M

Top Sells

Rank Stock Value
1
MDT icon
Medtronic
MDT
+$116M
2
ZNTL icon
Zentalis Pharmaceuticals
ZNTL
+$96.2M
3
GNMK
GenMark Diagnostics, Inc
GNMK
+$85.8M
4
BIIB icon
Biogen
BIIB
+$45.6M
5
BEAM icon
Beam Therapeutics
BEAM
+$38.2M

Sector Composition

Rank Sector Weight
1 Healthcare 97.73%
2 Consumer Staples 1.58%
3 Financials 0.69%
4 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
CTLT icon
51
DELISTED
CATALENT, INC.
CTLT
$33.5M 0.5%
310,111
-1,508
-0.5% -$162K
2020 Q1
5 quarters
ZYME icon
52
Zymeworks
ZYME
$1.85B
$32.6M 0.48%
939,697
-46,003
-5% -$1.46M
2020 Q1
5 quarters
AMED icon
53
DELISTED
Amedisys
AMED
$32.4M 0.48%
132,458
-522
-0.4% -$137K
2019 Q2
8 quarters
KLRS icon
54
Kalaris Therapeutics
KLRS
$51.2M
$31.3M 0.46%
68,874
-15,630
-18% -$8.07M
2020 Q3
3 quarters
LVTX icon
55
DELISTED
LAVA Therapeutics
LVTX
$30.6M 0.45%
2,816,196
-8,213
-0.3% -$102K
2021 Q1
1 quarter
RCEL icon
56
Avita Medical
RCEL
$410M
$29M 0.43%
1,411,117
-257,210
-15% -$5.07M
2020 Q3
3 quarters
ARDX icon
57
Ardelyx
ARDX
$849M
$28.2M 0.42%
3,714,100
+200,000
+6% +$1.48M
2019 Q4
6 quarters
BVS icon
58
Bioventus
BVS
$939M
$26.2M 0.39%
1,486,956
-13,044
-0.9% -$210K
2021 Q1
1 quarter
ZNTL icon
59
Zentalis Pharmaceuticals
ZNTL
$211M
$22.6M 0.34%
425,480
-1,795,564
-81% -$96.2M
2020 Q2
4 quarters
IMTX icon
60
Immatics
IMTX
$1.08B
$22.5M 0.33%
1,941,892
-140,922
-7% -$1.65M
2020 Q3
3 quarters
PPD
61
DELISTED
PPD, Inc. Common Stock
PPD
$21.5M 0.32%
466,471
-354,621
-43% -$16M
2020 Q1
5 quarters
BCEL
62
DELISTED
Atreca, Inc. Class A Common Stock
BCEL
$21M 0.31%
2,460,268
-30,300
-1% -$310K
2019 Q2
8 quarters
QSI icon
63
Quantum-Si Incorporated
QSI
$302M
$20.8M 0.31%
+1,700,000
New +$17.8M
2021 Q2
0 quarters
ACHL
64
DELISTED
Achilles Therapeutics
ACHL
$20.4M 0.3%
2,088,089
– –
2021 Q1
1 quarter
GRTS icon
65
DELISTED
Gritstone bio, Inc. Common Stock
GRTS
$20.3M 0.3%
2,226,206
-221,952
-9% -$2.05M
2018 Q3
11 quarters
ITMR
66
DELISTED
Itamar Medical Ltd. American Depository Shares
ITMR
$20.1M 0.3%
854,900
-64,000
-7% -$1.43M
2020 Q1
5 quarters
SNTI icon
67
Senti Biosciences Holdings
SNTI
$7.78M
$20M 0.3%
+201,290
New +$20.1M
2021 Q2
0 quarters
INNV icon
68
InnovAge Holding
INNV
$1.23B
$18M 0.27%
843,578
-6,422
-0.8% -$147K
2021 Q1
1 quarter
STXS icon
69
Stereotaxis
STXS
$104M
$17.9M 0.26%
1,855,504
-1,386,099
-43% -$10.9M
2019 Q3
7 quarters
TKNO icon
70
Alpha Teknova
TKNO
$416M
$17.2M 0.25%
+725,000
New +$18.3M
2021 Q2
0 quarters
HOOK icon
71
DELISTED
HOOKIPA Pharma
HOOK
$17M 0.25%
185,621
+1,331
+0.7% +$178K
2019 Q2
8 quarters
QTRX icon
72
Quanterix
QTRX
$146M
$14.1M 0.21%
240,933
-59,067
-20% -$3.43M
2021 Q1
1 quarter
PROF icon
73
Profound Medical
PROF
$235M
$12.9M 0.19%
787,346
-58,328
-7% -$1.09M
2020 Q1
5 quarters
TMCI icon
74
Treace Medical Concepts
TMCI
$268M
$10.1M 0.15%
+323,765
New +$10.3M
2021 Q2
0 quarters
CTSO icon
75
Cytosorbents Corp
CTSO
$9.45M
$9.85M 0.15%
65,218
-41,164
-39% -$6.94M
2020 Q3
3 quarters
1 2
3
4

Similar funds

FCM
Fairholme Capital Management South Miami, Florida $1.49B AUM 28.35% 1-Year Est. Return
MM
Main Management San Francisco, California $1.49B AUM 22.28% 1-Year Est. Return
WA
WBH Advisory Baltimore, Maryland $1.49B AUM 20.41% 1-Year Est. Return
ACB
Aristotle Capital Boston Boston, Massachusetts $1.49B AUM 32.81% 1-Year Est. Return
LCS
Levin Capital Strategies New York $1.49B AUM 30.44% 1-Year Est. Return
GAM
Gemmer Asset Management Walnut Creek, California $1.49B AUM 42.66% 1-Year Est. Return
MFWP
Mosaic Family Wealth Partners St. Louis, Missouri $1.49B AUM 26.43% 1-Year Est. Return
PMG
ProVise Management Group Clearwater, Florida $1.49B AUM 21.79% 1-Year Est. Return

Redmile Group's Q2 2021 Portfolio in Review

As of Q2 2021, Redmile Group held 93 positions worth $6.76B, down 4.8% from $7.1B the previous quarter. Its ten largest holdings account for 44% of the portfolio.

Redmile Group withdrew a net $367M in Q2 2021, closing 7 positions and reducing 55 holdings. Its most notable exit was Medtronic, an estimated $116M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, down from 99% a quarter earlier, followed by Consumer Staples and Financials.

Against the trend, Redmile Group opened a new position in Verve Therapeutics worth $117M.

  • Redmile Group's largest Q2 2021 buy was Verve Therapeutics: 1,936,530 shares worth $117M.
  • Redmile Group added most to SkinHealth Systems in Q2 2021, an estimated $59.8M increase.
  • Redmile Group's biggest Q2 2021 reduction was Zentalis Pharmaceuticals, cutting an estimated $96.2M.
  • Redmile Group fully exited Medtronic in Q2 2021, selling an estimated $116M.
  • Redmile Group's ten largest holdings make up 44% of its $6.76B portfolio in Q2 2021.
  • Redmile Group opened 7 new positions and closed 7 in Q2 2021.
  • Redmile Group's portfolio value fell 4.8% quarter-over-quarter to $6.76B.

Based on Redmile Group's 13F filing for Q2 2021, filed 16 Aug 2021.